Maris JM. Recent Advances in Neuroblastoma. N Engl J Med. 2010;362:2202–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KM, et al. COG Neuroblastoma Committee. Children’s Oncology Group’s 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2013;60:985–93.

Article  PubMed  Google Scholar 

Fan HJ, Huang C, Su Y, Wang XD, Ma XL. Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children. Zhonghua Er Ke Za Zhi. 2019;57:863–9.

CAS  PubMed  Google Scholar 

Jin Y, Lyu Q. Basic research in childhood cancer: progress and future directions in china. Cancer Lett. 2020;495:156–64.

Article  CAS  PubMed  Google Scholar 

Jin Y, Shi J, Wang H, Lu J, Chen C, Yu Y, et al. Myc-associated protein x binding with the variant rs72780850 in RNA helicase dead box 1 for susceptibility to neuroblastoma. Sci China Life Sci. 2020;64:991–9.

Article  PubMed  Google Scholar 

Brownhill SC, Burchill SA. PCR-based amplification of circulating RNAs as prognostic and predictive biomarkers – focus on neuroblastoma. Pract Lab Med. 2017;7:41–4.

Article  PubMed  Google Scholar 

Yue ZX, Xing TY, Zhao W, Zhao Q, Wang XS, Su Y, et al. MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma. Cancer Med. 2022;11:1837–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

El-Shazly SS, Hassan NM, Abdellateif MS, Taweel M, Ebeid EN. The role of β-catenin and paired-like homeobox 2b (phox2b) expression in neuroblastoma patients; predictive and prognostic value. Exp Mol Pathol. 2019;110: 104272.

Article  CAS  PubMed  Google Scholar 

Ambros IM, Tonini GP, Gross N, Mosseri V, Ptschger U, Beiske K. Age-dependency of the prognostic impact of tumor genomics in localized resectable MYCN non-amplified neuroblastomas Report from the SIOPEN Biology Group on the LNESG Trials. J Clin Oncol. 2018;38:3685–7.

Article  Google Scholar 

Kwon SY, Grisan V, Jang B, Herbert J, Badenhorst P. Genome-wide mapping targets of the metazoan chromatin remodeling factor nurf reveals nucleosome remodeling at enhancers, core promoters and gene insulators. PLoS Genet. 2016;12: e1005969.

Article  PubMed  PubMed Central  Google Scholar 

Zhao X, Zheng F, Li Y, Hao J, Tang Z, Tian C, et al. Bptf promotes hepatocellular carcinoma growth by modulating htert signaling and cancer stem cell traits. Redox Biol. 2019;20:427–41.

Article  CAS  PubMed  Google Scholar 

Pan L, Tang Z, Pan L, Tang R. Microrna-3666 inhibits lung cancer cell proliferation, migration, and invasiveness by targeting bptf. Biochem Cell Biol. 2019;97:415–22.

Article  CAS  PubMed  Google Scholar 

Cramer M, Xu R, Martin P. Soluble heparin binding epidermal growth factor-like growth factor is a regulator ofgalgt2expression andgalgt2-dependent muscle and neuromuscular phenotypes. Mol Cell Biol. 2019;39:e00140-e219.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boboila S, Lopez G, Yu J, Banerjee D, Kadenhe-Chiweshe A, Connolly EP, et al. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma. Oncogene. 2018;37:5451–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang T, Chen QF, Chang BY, Shen LJ, Fan WJ. TFAP4 promotes hepatocellular carcinoma invasion and metastasis via activating the pi3k/akt signaling pathway. Dis Markers. 2019;2019:7129214.

Article  PubMed  PubMed Central  Google Scholar 

Duan C, Wang H, Chen Y, Chu P, Xing T, Gao C, et al. Whole exome sequencing reveals novel somatic alterations in neuroblastoma patients with chemotherapy. Cancer Cell Int. 2018;18:21.

Article  PubMed  PubMed Central  Google Scholar 

Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.

Article  CAS  PubMed  Google Scholar 

Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27:289–97.

Article  PubMed  PubMed Central  Google Scholar 

Theodorakos I, Paterakis G, Papadakis V, Vicha A, Topakas G, Jencova P, et al. Interference of bone marrow CD56+ mesenchymal stromal cells in minimal residual disease investigation of neuroblastoma and other CD45- /CD56+ pediatric malignancies using flow cytometry. Pediatr Blood Cancer. 2019;66: e27799.

Article  PubMed  Google Scholar 

Kirberger SE, Ycas PD, Johnson JA, Chen C, Ciccone MF, Woo WL, et al. Selectivity, ligand deconstruction, and cellular activity analysis of a BPTF bromodomain inhibitor. Org Biomol Chem. 2019;17:2020–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann SM, Agarwala V, et al. DNA targeting specificity of RNA-guided cas9 nucleases. Nat Biotechnol. 2013;31:827–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun N, Yang Y, Wang S, Zhang J, Gui J, Tai J, et al. DCX and CRABP2 are candidate genes for differential diagnosis between pre-chemotherapy embryonic and alveolar rhabdomyosarcoma in pediatric patients. Pediatr Investig. 2021;5:106–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fulda S. The pi3k/akt/mtor pathway as therapeutic target in neuroblastoma. Curr Cancer Drug Targets. 2009;9:729–37.

Article  CAS  PubMed  Google Scholar 

Stankiewicz P, Khan TN, Szafranski P, Slattery L, Streff H, Vetrini F, et al. Haploinsufficiency of the chromatin remodeler bptf causes syndromic developmental and speech delay, postnatal microcephaly, and dysmorphic features. Am J Hum Genet. 2017;101:503–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Green AL, Desisto J, Flannery P, Lemma R, Vibhakar R. Bptf regulates growth of adult and pediatric high-grade glioma through the myc pathway. Oncogene. 2019;39:2305–27.

Article  PubMed  PubMed Central  Google Scholar 

Bagert JD, Mitchener MM, Patriotis AL, Dul BE, Wojcik F, Nacev BA, et al. Oncohistone mutations enhance chromatin remodeling and alter cell fates. Nat Chem Biol. 2021;17:403–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dar AA, Nosrati M, Bezrookove V, de Semir D, Majid S, Thummala S, et al. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy. J Natl Cancer Inst. 2015;107:1–9.

Article  Google Scholar 

Bi J, Liu H, Cai Z, Dong W, Jiang N, Yang M, et al. Circ-BPTF promotes bladder cancer progression and recurrence through the miR-31-5p/RAB27A axis. Aging (Albany NY). 2018;10:1964–76.

Article  CAS  PubMed  Google Scholar 

Dai M, Hu S, Liu CF, Jiang L, Yu W, Li ZL, et al. BPTF cooperates with p50 NF-κB to promote COX-2 expression and tumor cell growth in lung cancer. Am J Transl Res. 2019;11:7398–409.

CAS  PubMed  PubMed Central  Google Scholar 

Xiao S, Liu L, Lu X, Long J, Zhou X, Fang M. The prognostic significance of bromodomain PHD-finger transcription factor in colorectal carcinoma and association with vimentin and E-cadherin. J Cancer Res Clin Oncol. 2015;41:1465–74.

Article  Google Scholar 

Xu J, Wang Q, Leung E, Li Y, Fan X, Wu Q, et al. Compound C620–0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-cell lung cancer. Front Med. 2020;14:60–7.

Article  PubMed  Google Scholar 

Zhang C, Chen L, Liu Y, Huang J, Liu A, Xu Y, et al. Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma. Theranostics. 2021;11:3676–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Kong X, Sun P, Wang R, Li W, Chen Q. An integrated pan-cancer analysis of TFAP4 aberrations and the potential clinical implications for cancer immunity. J Cell Mol Med. 2021;25:2082–97.

Article  CAS  PubMed  Google Scholar 

Ma W, Liu B, Li J, Jiang J, Zhou R, Huang L, et al. MicroRNA-302c represses epithelial-mesenchymal transition and metastasis by targeting transcription factor AP-4 in colorectal cancer. Biomed Pharmacother. 2018;105:670–6.

Article  CAS  PubMed  Google Scholar 

Wang Y, Yang C, Liu X, Zheng J, Zhang F, Wang D, et al. Transcription factor AP-4 (TFAP4)-upstream ORF coding 66 aa inhibits the malignant behaviors of glioma cells by suppressing the TFAP4/long noncoding RNA 00520/microRNA-520f-3p feedback loop. Cancer Sci. 2020;111:891–906.

Article  CAS  PubMed  PubMed Central  Google Scholar